Giving and taking feedback
By Clare Gurton (clare.gurton@rxcomms.com) Somewhere inside all of us is the desire to be ‘good’ and to be liked. And, as a result, we may find we shy away from…
Details
Prevention information on the Internet
By Jonathan Coopersmith (jonathan.coopersmith@rxcomms.com) Benjamin Franklin said “An ounce of prevention is worth a pound of cure”. Perhaps the best way to reduce errors in medicine, then, is to prevent…
Details
Bridging cultural gaps
By Clare Gurton (clare.gurton@rxcomms.com) There is an increasing need for all of us to develop strategies for dealing with different cultures as business becomes more international and cross communication among…
Details
Observational studies: answering real-life questions about healthcare practice
By Ruth Whittington (ruth.whittington@rxcomms.com) Part 3 – Conducting an observational study Last month, we looked at the differences between observational studies and randomised controlled trials (RCTs). Here, we look at…
Details
Presenteeism and the impact of appropriate pharmaceutical treatment on workplace costs
By David Woods (david.woods@rxcomms.com) Question: “How many people work in the public sector?” Answer: “About half of them.” It’s an old one, to be sure, but it has its echo…
Details
Drowning in email? Here are some life belts
By David Woods (david.woods@rxcomms.com) If you feel that emails are inundating you, and you yearn for the days of the quill pen, help is at hand. In her recent book…
Details
ASHE revisited
By Amy Rothman Schonfeld (amy.schonfeld@rxcomms.com) One year after its first conference, the American Society of Health Economists (ASHE) is clearly thriving. Its membership has grown to more than 800, planning…
Details
ISPOR’s 12th annual international meeting
By David Woods (david.woods@rxcomms.com) The theme of this year’s international ISPOR meeting – held on May 20–23 in Arlington, Virginia, USA – was “new tools, new audiences for health outcomes…
Details
Observational studies: answering real-life questions about healthcare practice
By Ruth Whittington (ruth.whittington@rxcomms.com) Part 2 – How do observational studies and randomised controlled trials differ? Last month, I described observational studies and where they fit into the hierarchy of…
Details
HOC people: Alan Bakst
By David Woods (dwoods@rxcomms.com) “An opportunity and a challenge”. That’s what Alan Bakst found when he became Director of Health Economics and Outcomes Research at TAP pharmaceuticals in Chicago in…
Details